ACOEM Guidelines: Cannabis

Cannabis use is expanding rapidly, and a guideline is needed to address workplace issues. The ACOEM Guidelines methodology was used to develop an evidence-based guideline. There is some evidence suggesting potential efficacy of cannabis for treatment of spasticity associated with multiple sclerosis. There is no quality evidence of efficacy for treatment of common and typical work-related disorders such as back pain, chronic radiculopathy, neuropathic pain, and other acute or chronic pain disorders. There also is no quality evidence for perioperative use. There are many adverse effects, including cancers, cardiovascular diseases, psychotic disorders, and safety risks. There is rising concern cannabis may cause schizophrenia. Cannabis is not recommended for treatment of typical potentially work-related conditions. Cannabis use for any purpose is not recommended for those in safety-sensitive positions.